Within 2 years of reporting dasatinib-resistant mutations in BCR-ABL in a preclinical model, analogous mutations were recovered from dasatinib-resistant chronic myeloid leukemia patients (Burgess et al., 2005; Shah et al., 2007). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.